1 “Zydus” means Zydus Pharmaceuticals (USA) Inc., Nesher Pharmaceuticals (USA) LLC, and Zydus Lifesciences Limited, and any and all respective past and present direct or indirect parents, subsidiaries, divisions, affiliates, joint ventures, predecessors, successors, insurers, assigns, or shareholders related to each such entity.

In such capacity, Mr. Cohen shall take such actions he determines to be necessary and appropriate in connection with the establishment and administration of the Tribal QSF and the Zydus Settlement Trust funds to be held therein, including (without limitation) the creation of a trust to serve as the legal entity that operates and administers the Tribal QSF and the establishment of bank accounts3 to hold and distribute the funds held within the Zydus Settlement Trust and its sub-funds in accordance with the Zydus Settlement Agreement.

The fees of the Trustee/QSF Administrator and any fee panel members, advisors, vendors and services he determines to be necessary and appropriate to conduct and complete his work (including, without limitation, those incurred prior to the fulfillment of the conditions precedent of the Zydus Tribal Settlement Agreement), shall be paid for or reimbursed from the interest generated by the funds held within the Zydus Settlement Trust, or, thereafter, from the Zydus Settlement Trust funds.

3 Such accounts to be opened at Huntington Bank, or at another financial institution to be selected by the Trustee/QSF Administrator in his discretion and approved by the Court

Special Master David R. Cohen is hereby appointed to serve as Trustee and QSF Administrator for the 2025 Multi Defendant Tribal Opioid Settlement Trust qualified settlement fund established by this Order as further set forth above in this Order.